Expertise in
64
conditions

Jin Q. Li

No. 11 Guangqian Road, 
Suzhou, CN 
Expertise in
64
conditions
No. 11 Guangqian Road, 
Suzhou, CN 

Overview

Jin Li practices practicing medicine in Suzhou, China.

Li is highly rated in 64 conditions, according to our data. Their clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Liver Cancer, Alzheimer's Disease, Oophorectomy, and Endoscopy.

They are actively involved in clinical research, co-authoring 2390 peer reviewed articles and participating in 10 clinical trials.

Locations

No. 11 Guangqian Road, Suzhou, 215137, China
Other Locations
99 Shangda Road, Shanghai, 200444, China
209 Tongshan Road, Xuzhou, 221004, China
457 Zhongshan Road, Dalian, 116023, China
Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China
160 Pujian Road, Shanghai, 200127, China
136 Hanzhong Road, Nanjing, 210029, China
138 Tongzipo Road, Changsha, 410013, China
Kexue Avenue 100, Zhengzhou, 450001, China
283 Tongzipo Road, Changsha, China
369 Kunpeng Road, Hangzhou, 310008, China
145 Nantong Street, Harbin, 150001, China
No. 6, Shuangyong Road, Nanning, 530021, China
2School Of Ophthalmology And Optometry, 270 Xueyuan Road, Wenzhou, 325027, China
No. 76 Yanta West Road, Xi'an, 710061, China
2School Of Traditional Chinese Materia Medica, No. 121, Daxue Street, Taiyuan, 030619, China
No. 259 Xikang Road, Jing'an, China
100 Middle Street Of 4th Ring Road, Beijing, 100039, China
38 Xueyuan Road, Beijing, 100191, China
325 Guohe Road, Shanghai, 200433, China
100 West 4th Ring Middle Road, Beijing, 100039, China
109 Xueyuan Road, Wenzhou, China
No. 220, Handan Road, Shanghai, 200433, China
27 Taiping Street, Taiping, 100850, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies
A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies
Enrollment Status: Active_not_recruiting
Publish Date: May 11, 2026
Intervention Type: Drug
Study Drug: SKB264
Study Phase: Phase 1/Phase 2
A Phase Ia, Multicenter, Open-label Study of ILB2109 in Patients With Advanced Solid Malignancies
A Phase Ia, Multicenter, Open-label Study of ILB2109 in Patients With Advanced Solid Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2024
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characters, and Preliminary Efficacy of SCC244 in Patients with Advanced MET Alterations Solid Tumors
An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characters, and Preliminary Efficacy of SCC244 in Patients with Advanced MET Alterations Solid Tumors
Enrollment Status: Completed
Publish Date: November 01, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: Sitravatinib, Tislelizumab
Study Phase: Phase 1/Phase 2
A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients With Advanced Tumors
A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients With Advanced Tumors
Enrollment Status: Terminated
Publish Date: July 19, 2024
Intervention Type: Drug
Study Drug: HH2710
Study Phase: Phase 1/Phase 2
A Randomized, Open-Label, Dose-finding, Multi-centre, Phase Ib Study toEvaluate the Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors
A Randomized, Open-Label, Dose-finding, Multi-centre, Phase Ib Study toEvaluate the Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors
Enrollment Status: Completed
Publish Date: November 09, 2023
Intervention Type: Dietary supplement, Drug
Study Drug: JMT103
Study Phase: Phase 1
A Phase I/IIa Clinical Trial to Evaluate the Safety,Tolerability,Pharmacokinetics and Preliminary Effectiveness of IAE0972 in Patients With Advanced Malignant Solid Tumors.
A Phase I/IIa Clinical Trial to Evaluate the Safety,Tolerability,Pharmacokinetics and Preliminary Effectiveness of IAE0972 in Patients With Advanced Malignant Solid Tumors.
Enrollment Status: Unknown
Publish Date: July 19, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized, Open-label, Active-controlled, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of Roxadustat for Treatment of Anemia in Subjects Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
A Randomized, Open-label, Active-controlled, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of Roxadustat for Treatment of Anemia in Subjects Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
Enrollment Status: Completed
Publish Date: June 06, 2023
Intervention Type: Drug
Study Phase: Phase 3
An Exploratory Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody) Combined With Chemotherapy in Patients With Advanced Solid Tumors.
An Exploratory Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody) Combined With Chemotherapy in Patients With Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: April 12, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase I Study of CM082 Tablets in the Treatment of Advanced Malignant Solid Tumors: Safety, Tolerance and Pharmacokinetics
Phase I Study of CM082 Tablets in the Treatment of Advanced Malignant Solid Tumors: Safety, Tolerance and Pharmacokinetics
Enrollment Status: Unknown
Publish Date: November 14, 2022
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

2385 Total Publications

Structure and function of word laterality in early childhood.
Structure and function of word laterality in early childhood.
Journal: Behavioral neuroscience
Published: August 13, 2026

Frequently Asked Questions about Jin Q. Li

Is Jin Q. Li a top-rated expert for Head and Neck Squamous Cell Carcinoma (HNSCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Jin Q. Li is classified as an Distinguished expert for Head and Neck Squamous Cell Carcinoma (HNSCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jin Q. Li participate in research or clinical trials?

Yes. Jin Q. Li has published 2385 articles and abstracts on conditions like Head and Neck Squamous Cell Carcinoma (HNSCC). You can view a list of Jin Q. Li's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Li's expertise for a condition
ConditionClose
    View All 63 Advanced Conditions
    View All 266 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile